Round Two: Mevacor Switch Will Need To Quiet Questions On Non-Optimal Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Undertreatment concerns remain biggest hurdle for Mevacor (lovastatin) switch sponsor J&J/Merck when the statin goes before a second advisory committee review expected in the next 12 months.